The firm issued 1.575mln units as payment of $504,000, which was the total amount due under all the debentures.
Showing 25 of 5064
VentriPoint Diagnostics shares shot up by a fifth on Wednesday after the company said it is increasing the maximum gross proceeds of its non-brokered private placement to C$3.2mln from C$2mln and will now issue up to 10 million units at 32 cents per unit
The biopharma company said it has made progress on the development of several cancer treatments
VentriPoint Diagnostics said it intends to complete a non-brokered private placement of up to 6.25mln units at 32 cents per unit for total gross proceeds of up to C$2mln
The target date for the FDA to complete its sNDA review is 6 November, 2017.
Drugs and treatment group M Pharmaceutical Inc on Monday announced that Kim Whittemore has been appointed to its board of directors
Concert Pharmaceuticals has swung to a full year loss after revenue plunged but shares have jumped on news that Vertex Pharmaceuticals is buying its cystic fibrosis assets
The drug developer now has around US$40mln in the bank, which should see it through to the fourth quarter of 2018
CytoSorbents Corp. is seeking US approval for the distribution of its CytoSorb blood filters, designed to reduce inflammation life-threatening illnesses such as sepsis
Innovus will now be able to sell the sexual arousal disorder treatment in all 28 member countries of the European Union
The drug developer has trials underway for treatments for Duchenne muscular dystrophy and Clostridium difficile infection.
Exelisis will combine Cabometyx with blockbuster PD-1 immunotherapy drug Opdivo (nivolumab)
The firm will receive an initial tranche of £2 million, available on signing..
VolitionRx Limited will attend the BTIG 2017 Medical Technology, Life Sciences, and Diagnostics Conference being held from February 28 - March 3 in Snowbird, UT
Thompson added that the firm looked forward to further additions to the board.
“This is a significant step in the development of M Pharma as a company," said company boss Gary Thompson.
In the clinical trials, patients treated with Siliq had shown suicidal behaviour, the FDA said
HMPL-453 targets fibroblast growth factor receptors, which are central to several biological processes
M Pharmaceutical Inc. has appointed Gary Thompson as its president and chief executive officer
With the closure of that acquisition, the firm gains around seven different products, which are FDA cleared.
The grant was awarded by the Australian Federal Government.
VolitionRx Limited will present at Source Capital Group's 2nd Annual Disruptive Growth & Healthcare Conference being held on February 15-16 in New York
After a disappointing previous three months, the Dublin-based pharma beat expectations this time.
The trial involved 31 boys taking different doses of edasalonexent.
“I was pleased with the company’s overall performance during 2016," said chief executive Ian Read.